Whether its optimizing performance, stabilizing conditions, or facilitating healing, we leverage the therapeutic potential of BPC-157 to support your goals
A method of preventing gait abnormalities in a patient with Parkinson's disease or of improving or restoring to normal the gait of a patient with Parkinson's disease, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to prevent, improve or restore to normal said gait, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 where Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
The British Society for Haematology (BSH) published their Guidance on treating Pernicious Anaemia during Covid-19 two weeks ago
In some embodiments, any formulation or composition described herein has a pH that allows for sterilization (e.g., by filtration or aseptic mixing or heat treatment and/or autoclaving (e.g., terminal sterilization)) of a formulation or composition without degradation of the therapeutic agent
Surgery 232 (2), 199201
"Nicotinamide N-methyltransferase: More than a vitamin B3 clearance enzyme." Trends in Endocrinology & Metabolism (2017)
